Literature DB >> 2192412

Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. The Canadian Erythropoietin Study Group.

A Laupacis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2192412

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN： 0270-9295            Impact factor:   5.299


× No keyword cloud information.
  4 in total

1.  Ethnicity, socioeconomic status, and attainment of clinical practice guideline standards in dialysis patients in the United kingdom.

Authors:  Udaya P Udayaraj; Yoav Ben-Shlomo; Paul Roderick; Retha Steenkamp; David Ansell; Charles R V Tomson; Fergus J Caskey
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-08       Impact factor: 8.237

2.  A review of the first year of Medicare coverage of erythropoietin.

Authors:  R I Griffiths; N R Powe; J Greer; G de Lissovoy; G F Anderson; P K Whelton; A J Watson; P W Eggers
Journal:  Health Care Financ Rev       Date:  1994

Review 3.  Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.

Authors:  Suetonia C Palmer; Valeria Saglimbene; Dimitris Mavridis; Georgia Salanti; Jonathan C Craig; Marcello Tonelli; Natasha Wiebe; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2014-12-08

Review 4.  Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients.

Authors:  Deirdre Hahn; June D Cody; Elisabeth M Hodson
Journal:  Cochrane Database Syst Rev       Date:  2014-05-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.